Rituximab versus a watch-and-wait approach in patients with advanced- stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial


Ardeshna K. M. , Qian W., Smith P., Braganca N., Lowry L., Patrick P., ...Daha Fazla

LANCET ONCOLOGY, cilt.15, sa.4, ss.424-435, 2014 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 15 Konu: 4
  • Basım Tarihi: 2014
  • Doi Numarası: 10.1016/s1470-2045(14)70027-0
  • Dergi Adı: LANCET ONCOLOGY
  • Sayfa Sayıları: ss.424-435

Özet

Background Patients with advanced-stage, low-tumour-burden follicular lymphoma have conventionally undergone watchful waiting until disease progression. We assessed whether rituximab use could delay the need for chemotherapy or radiotherapy compared with watchful waiting and the effect of this strategy on quality of life (QoL).